User:Mr. Ibrahem/Carfilzomib

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Carfilzomib
Clinical data
Trade namesKyprolis
Other namesPX-171-007
AHFS/Drugs.comMonograph
MedlinePlusa612031
License data
Pregnancy
category
  • AU: C
Routes of
administration		Intravenous
Drug classProteasome inhibitor[1]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only[2]
  • EU: Rx-only
Pharmacokinetic data
Protein binding97%[2]
MetabolismExtensive; CYP plays a minor role
Identifiers
  • (2S)-4-Methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide
Chemical and physical data
FormulaC40H57N5O7
Molar mass719.924 g·mol−1
3D model (JSmol)
  • O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)[C@@]1(OC1)C)CC(C)C)Cc2ccccc2)CC(C)C)CCc3ccccc3)CN4CCOCC4
  • InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1
  • Key:BLMPQMFVWMYDKT-NZTKNTHTSA-N

Carfilzomib, sold under the brand name Kyprolis, is a medication used to treat multiple myeloma (MM).[1] It is used in those who have not improved with other treatment.[4] It is given by injection into a vein.[4]

Common side effects include low red blood cells, tiredness, nausea, diarrhea, low platelets, fever, shortness of breath, cough, and low white blood cells.[3] Other side effects may include heart problems, liver problems, lung problems, kidney problems, bleeding, infection, and high blood pressure.[3] Use in pregnancy may harm the baby.[5] It is a proteasome inhibitor.[1]

Carfilzomib was approved for medical use in the United States in 2012 and Europe in 2015.[1][3] In the United Kingdom it costs the NHS about £1,050 for 60 mg as of 2021.[4] In the United States this amount costs about 2,700 USD.[6]

References[edit]

  1. ^ a b c d e "Carfilzomib Monograph for Professionals". Drugs.com. Archived from the original on 9 June 2021. Retrieved 30 December 2021.
  2. ^ a b "Kyprolis- carfilzomib injection, powder, lyophilized, for solution". DailyMed. 26 August 2020. Archived from the original on 12 August 2020. Retrieved 13 November 2020.
  3. ^ a b c d "Kyprolis". Archived from the original on 14 November 2021. Retrieved 30 December 2021.
  4. ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1008. ISBN 978-0857114105.
  5. ^ "DailyMed - KYPROLIS- carfilzomib injection, powder, lyophilized, for solution". dailymed.nlm.nih.gov. Archived from the original on 12 August 2020. Retrieved 30 December 2021.
  6. ^ "Kyprolis Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 8 February 2018. Retrieved 30 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Carfilzomib&oldid=1099698208"